Edity is a company headquartered in Israel.
Edity develops an AI-powered immune cell delivery platform that engineers therapeutic proteins for targeted intracellular delivery, aiming to treat diseases including solid tumors by reprogramming the tumor microenvironment.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.